VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017
October 17, 2017 08:00 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Oct. 17, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced the company's abstract, "Antibody and Cell-mediated Immunity...
VBI Vaccines to Present at The World Vaccine Congress Europe 2017 in Barcelona
October 11, 2017 08:00 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Oct. 11, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced that Adam Buckley, vice president of business development, will...
VBI Vaccines to Present at September 2017 Investor Conferences
September 12, 2017 08:00 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Sept. 12, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will provide a corporate...
VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program
August 30, 2017 08:00 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Aug. 30, 2017) -
Sci-B-Vac® is a third-generation hepatitis B vaccine, approved for use in Israel and 14 other...
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
August 28, 2017 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Aug. 28, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced that David Anderson, Ph.D., Chief Scientific Officer of VBI, will...
VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme
August 15, 2017 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Aug. 15, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation...
VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine
July 27, 2017 07:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - July 27, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation...
VBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac(TM) Hepatitis B Vaccine
July 11, 2017 16:05 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - July 11, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") announced today its plans for a global Phase 3 clinical program for...
VBI Vaccines Announces Results of Annual General and Special Meeting
June 28, 2017 17:00 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 28, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") today announced the voting results from its annual general and special meeting...
VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes
June 26, 2017 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 26, 2017) - VBI Vaccines, Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation...